Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Why Toxicology and Safety Studies in 6 months? BASi has the Culex-L (big animals) and Culex ABC (for small animals).
Yes, and it is not "blind faith" but faith based on NanoViricides, Inc. history of steadily andvancing to where no other company has gone before, in their quest to eradicate viral diseases. Eradicating viral diseases is our business.
Solutions to many of our problems will come from small towns in the U.S., and around the globe, if people are let alone, if they are given more freedom to act. After all, we are the ones that pay the bills in this country and elsewhere.
Enjoy!
I meant a whole lot of sense to Big Pharma in the vaccine business. But, NanoViricides, Inc. is not interested for now...remember this?
When people fret about management decisions of a publicly traded company, why not take a walk down memory lane?
Exacto mundo! To put it mildly, bizarre!
Dr. S is managing the objective(s) and job one, as drkazmd65 alluded to in his post, is the FluCide candidate. He is meeting with the executive officers, board of directors, communicating with partners/collaborators...he is focused/involved in activities to manage the objective(s) and take FluCide to the clinical trials and FDA review.
After spending $140M...and managing the objectives for Tekmira's TKM-Ebola I would say the question is, Where is it? Can Tekmira approach government(s) once again for more money and deliver their drug to West Africa? Why hasn't it happened? or has it? If Tekmira is failing to get government(s) interest on TKM-Ebola what are NanoViricides, Inc. prospects?
Thanks Rearden. I am retiring for the evening and I will access the account tomorrow morning. Go NNVC!!!
Soon enough the cGMP Pilot Plant will have its certificate of occupancy and the fun time will begin with efficacy studies. If the "good doctors" have not expressed concern with the "tox package", as far as I'm concerned, I am at ease. No worries!
To whom it may concern. Communicating from remote computer and I've been locked out from personal email account for 12 hours. Horse feathers...it happens!
Echo20, if the human dose is 1 teaspoon, perhaps the current lab produces 800 - 1000 a week...??? I am guessing. I hope I am wrong too. I think this question would be good for the BigKahuna. It is a good question IMO and I've meant to ask the forum/posters. Good luck.
It is scary indeed...
Echo20, I don't think NanoViricides, Inc. will spare precious resources to further develop EbolaCide unless Ebola is declared a potential threat to public health and national security and has the flexible cGMP Pilot Plant up and running (we can then deliver for compassionate/emergency use). They are already using their resources to advance the FluCide candidate, DengueCide, HIV, MERS, etc...Do you know if the current government administration has declared Ebola a potential threat to the nation? or unless NanoViricides, Inc. anticipates such declaration? Does anyone in the U.S. Congress know that our small company transformational technology is capable of doing, in which case our small company would be tapped for the task?
Excellent! Your father is healing and that means you and your family are healing with him as well(less and less suffering).
"And by the river upon the bank thereof, on this side and on that side, shall grow all trees for meat (food), whose leaf shall not fade, neither shall the fruit thereof be consumed: it shall bring forth new fruit according to his months, because their waters they issued out of the sanctuary: and the fruit thereof shall be for meat, and the LEAF thereof FOR MEDICINE" (Ezek. 47:12).
I was looking at dosage and the oral regimen of Sovaldi.
http://reference.medscape.com/drug/sovaldi-sofosbuvir-999890
I read nanopatent's post and the U.S. Congress concern for cost $84K. Perhaps the U.S. Congress should help bring a little competition to market from a small company, NanoViricides, Inc. Once the Toxicology and Safety studies are complete, take our small company and low toxicity drugs straight to the Clinical Trials...it will be just a few short months as Doctor Seymour has asserted in the past!
Thank you nnvcbob. I did see your recent post,
Oops...I take from your post that you will soon be posting again with an excerpt on the "flawless" science/empirical evidence behind current vaccines. I don't think anyone here would object to that as long as you post something about nanoviricides transformational technology like, for example...
One word of caution to the NNVC naysayers...the PR statement, "...The Company intends to begin the [GLP]safety/toxicology studies of this Injectable FluCide™ drug candidate as soon as feasible, and is producing sufficient drug substance for these studies at its existing facility..." IMHO, is a statement of aim or purpose by our small company. There is no additional statement expressing "Tox studies" will start next month or will start in the near future nor denies they have already started therefore, don't be surprised if what nanopatent described as "doubling overnight" or "triple" actually happens. All it will take is blockbuster news about our cGMP Pilot Plant being commissioned first...
In my opinion, Pump Terminator was just a "hit job" to acquire more shares of NNVC at a lower price or worse, a hit job from companies that wouldl be significantly and adverse financially affected by the company's disruptive technology. They were falsehoods based on vague conjecture, not about the science behind the company but about finances of this small company. Not one ounce of proof of their claims before any court of law in the U.S.!
People/investors may be better served by contacting the independent collaborators of NNVC. Are independent collaborators in agreement or do they have any reservations as to the company Press Releases?
1- US Army Medical Research Institutute for Infectious Diseases (USSAMRIID)
WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), announced today that the broad-spectrum nanoviricides™ drug candidates were found to be highly effective against the deadly Ebola virus in initial cell culture studies by scientists at the United States Army Medical Research Institute of Infectious Diseases (USAMRIID).
2- LSU School of Veterinary Medicine
NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), has announced that the herpes simplex viral load was reduced by 99.99% or 10,000 fold in in-vitro studies by nanoviricides™ drug candidates.
The studies were performed by Thevac in Baton Rouge, LA, in collaboration with the Division of Biotechnology and Molecular Medicine at the LSU School of Veterinary Medicine under the supervision of Dr. Gus Kousoulas.
3- University of California, Berkeley, School of Public Health
... There is currently neither an effective drug treatment nor a vaccine for dengue virus infection. The FDA has recently awarded orphan drug status to DengueCide and the Company is pursuing similar status with the European Medicines Agency (EMA). The orphan designation enables the Company to undertake rapid drug development following its influenza drug candidates.
“Our relationship with Dr. Harris and her colleagues is critically important to our development program for DengueCide,” said Eugene Seymour, MD, MPH, CEO of NanoViricides. Dr. Harris has an excellent mouse model of dengue virus infection and disease that the Company used previously to evaluate its anti-dengue agents. In those studies, the nanoviricides® have shown high effectiveness. In Prof. Harris’ model of dengue vascular leak, dengue virus infection of the laboratory mouse strain, AG129, is 100% fatal when the mice are untreated. In contrast, in the same study, animals treated with one of NanoViricides' anti-dengue agents achieved an unprecedented 50% survival rate.
4- US Centers for Disease Control and Prevention
WEST HAVEN, Conn.--(BUSINESS WIRE)--August 04, 2008 NanoViricides, Inc. (OTC BB: NNVC.OB), (the "Company") said that it has signed a Materials Cooperative Research and Development Agreement (MCRADA) with the United States Centers for Disease Control and Prevention (CDC) in Atlanta, Georgia for rabies treatment study. The study, to be performed in collaboration with the CDC Rabies Program, is scheduled to begin soon.
"This study will expand on two successful animal studies of RabiCide(TM)-I performed previously by the government of Vietnam," said Eugene Seymour, MD, MPH, CEO of the Company, adding that "In those prior studies we achieved a 25% to 30% survival rate in animals that had already developed rabies. We believe this strong survival rate is a historical first achievement for any post-infection rabies treatment."
5- Feinstein Institute of Medical Research
WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), reports that Dr. Vivien Boniuk, Associate Professor of Ophthalmology, Albert Einstein College of Medicine, associated with the North Shore Long Island Jewish Health System (NSLIJ), will be presenting additional results from the animal studies on nanoviricide drug candidates against Epidemic Kerato-Conjunctivitis (EKC). These studies were conducted at the Feinstein Institute for Medical Research of the NSLIJ. Dr. Boniuk will be speaking at the GTC-Bio Conference on Ocular Diseases and Drug Discovery on April 21 in Philadelphia, PA.
There are more collaborators you can find in the video (advance to 16:28) in order for investors to do their research...
Any comments on pump terminator, whose future hangs in the balance???
Is it possible for NNVC to have the new cGMP Pilot Plant <<lab>> licensed for GLP (pre-clinical) first? I figure the same license as the lab in West Haven, CT. If yes, we must be using the cGMP plant lab for FluCide production to capacity (5kg), just as we are using the small lab GLP GMP-like (batches) at West Haven, CT to capacity(sub kg). NanoViricides, Inc. does not conduct tests with animals at the lab(s), strictly non-clinical. Next, the cGMP Pilot Plant can be licensed in its totality for clinical tests/production, soon. Possible?
The landing on the moon changed technology history and NanoViricides, Inc. is about to make history with the fast-acting, low toxicity, life-saving, highly effective therapeutic drug, FluCide. FluCide will not care if you are young or old, if you have a compromised immune system or not, it is agnostic to the host of a life threatening virus.
Here is some more information on BASi fast,reliable, Toxicology Services with their proprietary system, CULEX...
Preclinical Toxicology Services
Our AAALAC-accredited laboratory has been providing clients with drug safety and toxicology data for over 40 years. Located on a 52-acre campus in a rural setting near Evansville, Indiana, our preclinical research facility occupies a total of 90,000 square feet in 11 buildings. BASi is large enough to have all the resources and experience to complete your projects expertly and on time, yet small enough to be flexible and responsive.
GLP Toxicology Services
BASi provides clients with fast, reliable, preclinical in-life and pathological data in compliance with federal guidelines. Clinical pathology, clinical chemistries, analytical method development and validation, PK/TK data analysis and histopathology laboratories offer in-house assessment of biological samples and test articles.
Toxicology Services include:
-General toxicology services
Acute
Sub-chronic
Chronic
-Carcinogenicity studies
-Behavioral toxicology
-Immunotoxicology and biomarkers
-Clinical chemistry and pathology panels
-Necropsy and histology with special stains
-Pharmacokinetics and drug metabolism
source: http://www.basinc.com/services/toxicology/preclinical.html
Here is a bit more on NanoViricides, Inc. clinical trials in Australia strategy...
Australia Early Phase Advantage ----
There are lots of reasons to want to execute your early phase clinical trials in Australia. The population profiles and the high standard of clinical facilities make it a cost effective alternative to Europe or the USA. But more than anything else, it is the outstanding advantage of a fast and pragmatic regulatory pathway for phase 1-2 studies that makes our region such an attractive place for Biotech companies to conduct initial clinical trials.
The availability of the Clinical Trials Notification (CTN) Scheme means that our clients can put the need to submit full regulatory submissions to the FDA, EMA, etc. to one side and submit directly to Australian Ethics Committees (IRBs) who under the CTN scheme assume the typical regulatory review responsibility. This review is done within a usual review cycle of 4-8 weeks based upon a protocol, investigator brochure and perhaps an independent toxicology report. The result is a much faster timeline into the clinic, avoiding lengthy Regulatory Authority reviews and costly submission dossiers meaning better use of limited funding available to many small Biotechnology companies.
Perhaps the most important element in NanoViricides, Inc. strategy to the clinical trials and the market...Australia!!!
When speaking to people out there, from all walks of life, remember this key selling point...
NanoViricides, Inc. is going to Australia to gain approval for their low toxicity/safe, effective and life-saving drug, FluCide!
Australia ranks third behind Hong Kong and Singapore as the one of the economies considered 'free' with economic freedom scores above 80 on the 0-to-100 Index scale. It has held this position since 2009.
Substantial score increases in six of the 10 components of economic freedom, including business freedom, investment freedom, and freedom from corruption, have enabled the country to achieve and sustain its economically 'free' status in the Index.
The survey states that Australia continues to set the standard for clean, corruption-free government and benefits significantly from its transparent and efficient business environment, and open-market policies.
more: http://www.cato.org/economic-freedom-world
The Australian government reimburses 45 percent of research and development expenses.
FDA Doings: Always in the Crosshairs
by Michael Jorrin, "Doc Gumshoe" | February 19, 2014 9:23 am
[Ed note: Following is another installment from our favorite medical scribe, "Doc Gumshoe" (no, he's not a doctor). We feature Michael's commentary every couple weeks or so, and his thoughts and words are his own. "Doc" doesn't pick stocks, but FDA decisions are a huge driver of investment success for pharmaceutical and biotech companies and today Michael does some explaining about how the FDA and clinical trials work.]
Readers of this blog have a pretty wide range of opinions about the FDA, although the more outspoken of you mostly chime in with negative comments. Doc Gumshoe, being aware of the many stark conflicts between the FDA and drug companies, is a skeptic regarding the view that the FDA is in cahoots with Big Pharma. But this little piece looks at a few areas where the FDA’s recent practices have been subject to criticism from elevated sources. Before I go on to cite chapter and verse, I should recap some of the specific hurdles that the drug and device approval process has to leap over.
What does a treatment have to demonstrate to gain FDA approval?
The answer, in two words (plus a conjunction) is efficacy and safety. That goes for any intervention, whether it’s a drug or a device or any other kind of treatment. But how can that be demonstrated? If we’re talking about a drug, the gold standard is the randomized, placebo-controlled clinical trial, in which the candidate drug demonstrates at least some advantage over an existing drug. The advantage could be with regard to any of several parameters – a greater percentage of patients attaining a specific marker, a more rapid onset of action or a longer duration of action, a lower incidence of adverse effects, and a number of others. And this advantage needs to be statistically significant, meaning that the results of the clinical trial must be highly unlikely to have been a matter of chance.
There are lots of obstacles that the pharma company has to overcome. Here are just a few:
If there are already some fairly effective existing drugs for a disease, it’s likely to be difficult to enroll patients in a trial where the patient would not know whether he/she was going to get the existing drug, or a placebo, or a new experimental drug.
If the trial calls for patients/subjects who have never taken a drug for that disease or condition – drug-naïve patients, as they are known – it may be exceedingly difficult to recruit enough patients for the kind of big Phase 3 trials the FDA likes to see. Patients newly diagnosed with a disease or disorder want to be treated with a drug that is known to work.
Then there’s the issue of diseases/disorders/conditions that don’t affect large numbers of people. Again, in such cases, it may be difficult or impossible for drug companies to enroll enough patients for multiple clinical trials.
For those reasons (and others) lots of trials are now being conducted in the so-called “less developed” parts of the world, and sometimes, perhaps, with less rigorous standards than would be expected.
… and, of course, there’s another issue …
Namely, how long it takes for some drugs to get approved and available for treatment. We all remember the early days of the AIDS epidemic. When there was something like a promising drug coming along, there was intense pressure to get that drug to people who were dying of AIDS. That got a lot of publicity, and the FDA got it in the neck for being “obstructionist” – that is, for insisting on going through the time-consuming approval process.
The FDA, to some degree, initiated changes in their procedures – mostly a matter of streamlining the bureaucracy and simplifying procedures.
But in response to the clear need to speed things along – get drugs to the patients who need them – the FDA has also instituted some changes in the requirements for approval, specifically for some medical conditions, based on such issues as limited availability of treatment options and urgency of getting some kind of treatment to patients who might have rapidly deteriorating illnesses.
“Breakthrough Therapy Designation,” or BTD
Here’s a statement directly from the FDA:
Fact Sheet: Breakthrough Therapies
On July 9, 2012 the Food and Drug Administration Safety and Innovation Act (FDASIA) was signed. FDASIA Section 902 provides for a new designation – Breakthrough Therapy Designation. A breakthrough therapy is a drug: intended alone or in combination with one or more other drugs to treat a serious or life threatening disease or condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development.
If a drug is designated as breakthrough therapy, FDA will expedite the development and review of such drug. All requests for breakthrough therapy designation will be reviewed within 60 days of receipt, and FDA will either grant or deny the request.
Please refer to section 902 of FDASIA for more specific information about this provision. Additionally, a draft Guidance for Industry: Expedited Programs for Serious Conditions––Drugs and Biologics was published on June 25, 2013, and includes information such as qualifying criteria for breakthrough therapy designation, features of the breakthrough therapy program, and guidelines on how to submit a breakthrough therapy designation request.
As of the beginning of 2014, the FDA had received over 100 breakthrough therapy designation (BTD) requests and approved only about 30%. They declined about 60% and another 10% or so are currently pending.
source: http://www.stockgumshoe.com/2014/02/fda-doings-always-in-the-crosshairs/print/
NanoViricides Signs a Non-Disclosure Agreement with the Lovelace Respiratory Research Institute for IND-enabling Efficacy Studies on FluCide® and for Testing its Novel Drug Candidates against the Highly Lethal MERS Human Coronavirus
August 05, 2013 07:00 AM Eastern Daylight Time
WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB: NNVC) (the "Company") said it has signed a non-disclosure agreement (NDA) with the Lovelace Respiratory Research Institute (“LRRI”). The Company intends to enter into a Master Services Agreement with LRRI for the IND-enabling efficacy studies of both its broad-spectrum injectable and oral FluCide® drug candidates. These studies will employ multiple unrelated subtypes and strains of Influenza A, including the novel H7N9 strain, the subtype which is currently circulating in China. The Company has already shown that the injectable and oral FluCide drug candidates are substantially more effective than oseltamivir (Tamiflu®) in controlling influenza A virus infections in a highly lethal animal model using two unrelated subtypes of influenza A, namely H1N1 and H3N2. In addition to FluCide, LRRI will also be able to evaluate the Company’s anti-MERS drug candidates in cell culture and animal models when available. The NDA enables the scientists at the Company and LRRI to exchange confidential and proprietary information in preparation for the intended studies.
The injectable FluCide drug is intended for severely ill hospitalized patients while the follow-on oral drug is intended for use in out-patients. Following advice from the Company’s pre-IND meeting with the FDA, the Company intends to evaluate both drugs against multiple unrelated subtypes of influenza A in animal models and in cell culture studies.
H7N9 is a novel subtype currently circulating in China. Recent studies have indicated that it is a potential pandemic threat. H7N9 was found to be less sensitive to approved drugs than the H1N1/2009 pandemic strain. See New studies on H7N9 raise pandemic concerns | CIDRAP (http://www.cidrap.umn.edu/news-perspective/2013/07/new-studies-h7n9-raise-pandemic-concerns).
The Company has recently developed drug candidates for evaluation against the novel MERS h-CoV (“Middle East Respiratory Syndrome human Coronavirus”). The Obama administration has designated MERS as a potential threat to public health and national security, on June 4, 2013. Administration declares Mideast flu a potential public health emergency - The Hill's Healthwatch (http://thehill.com/blogs/healthwatch/public-global-health/303441-administration-declares-mideast-flu-a-potential-public-health-emergency). No drugs or vaccines are available against MERS h-CoV.
The Company has recently executed a NDA with the UK Public Health Agency that is intended to lead to a Master Service Agreement for the evaluation of FluCide against the novel A/H7N9 influenza strain as well as evaluation of the Company’s novel drug candidates against the newly emerging MERS human Coronavirus. The Company believes that independent testing of our drug candidates at these two sites should result in a dataset providing a high degree of confidence.
UK Public Health Agency - Testing for Influenza and MERS
Thanks FN, but I am always leery about posting any personal information in any public forum and I post in very few. I prefer to exchange information in person, or just before we meet in Hawaii (or other location). Cheers!
Dr. Ms. Weedie, thank you for your kind words.
As you well know, Nanoviricides, Inc. has transformational technology that could significantly impact life for the better in our planet. I particularly will use the latest presentation by Dr. Seymour, Eradicating Viral Diseases, which is superb, to say the least!
When it comes to NNVC, I am unstoppable in my attempt to describe our small company (small now but not for long) and its transformational technology to many others I encounter. I spread the word on Nanoviricides, Inc. to those that may even not be buying, just to create awareness. My closing words to those that likely may not be buying shares in great numbers, "...pause all money consuming activities for a year and if at all possible, start to buy 100 shares a month for a year...or remember the name of the company, Nanoviricides, Inc. (NNVC) because it won't be long before you see it featured in more tv/radio newscasts and science journals worldwide...you will then remember our brief conversation and rejoice in the knowledge that protection of your health, that of your family, friends and neighbors is at hand...".
Posters on the nnvc board: larson1, Rearden, nanopatent, robi-1-kenobi, ZincFinger, Puffer, BigKahuna, Echo20, leifsmith, I need help, found_it_two, Detonate, nnvcbob, S_Colton, another_voice_2, FORZANANO, crashco, GaryR, thefamilyman, incubus-now, Churchboy7, Benjii, CrossBone09, drkazmd65, rosalieone, maninos, lousyengineer, lookatthesky, Aspenmp, KMBJN, Diabolical_Southpaw, significant others and last but not least you with your contagious optimism!
Gooooooooooooo NNVC!!!
p.s. I'm sorry if I don't mention others as all are significant posters and thank GOD the list is long and it is getting longer
I am returning to my home state today. I spoke with a doctor/surgeon at a wedding, a couple of weeks ago, and as I described Nanoviricides, Inc. key characteristics he rose his head to the heavens and exclaimed, Oh, wow...! He immediately grabbed his iPad and asked me to give him the name of our small company and symbol. Then he proceeded to ask me, "...do they have a drug for HIV/AIDS?" to what I replied, YES! Their "...lead anti-HIV drug candidate achieved a long term anti-HIV effect with a much shorter dosing regimen and a markedly lower total drug dose than HAART drug cocktail therapy in a recent animal study. The antiviral effect of the anti-HIV nanoviricide (“HIVCide™”) continued throughout the 48 days of study even though HIVCide dosing was discontinued after only 20 days." As we walked he said, "...how is it possible that Bill Gates is unaware of this??? He may not be aware of it because he may be involved with Big Pharma's quest for a standard drug treatment for HIV/AIDs but who knows, he may be aware of our small company already.
I also spoke with a New York biotech employee, maker of vaccines, and he also expressed great interest in our small company.
I have spoken to all walks of life people, with the drive of a madman, to let them know that help against viral disease is on the way and that is up to everyone of us to learn more about it and let others know about a small company with transformational nanotechnology, a small company to become one of the most beneficial companies in the history of mankind.
We are waiting for a barrage of good news, that we've read before but this time meeting all FDA requirements for clinical trials 2015, good news that will propel this company to new highs, to the stock market stratosphere...ignition sequence start! Rejoice, the life-saving medicines of our small company are going to market soon!
On the subject box type GLP and you will get all posts on that subject...
Pre-clinical development: GLP vs. GMP
In drug development, pre-clinical development, also named preclinical studies and nonclinical studies, is a stage of research that begins before clinical trials (testing in humans) can begin, and during which important feasibility, iterative testing and drug safety data is collected.
The main goals of pre-clinical studies are to determine a product's ultimate safety profile. Products may include new or iterated or like-kind medical devices, drugs, gene therapy solutions, etc.
source: http://en.wikipedia.org/wiki/Pre-clinical_development
Big Pharma cannot back "the Cides" because....
And the winner is NanoViricides, Inc.!!!...because it does not care if the host to the virus is a child or an elderly person, it does not care if the immune system of the host is compromised or not and:
1- The FluCide candidate has been found to be 1500x more effective than Tamiflu
2- Nanoviricides have been proven on 6,000+ animals and found to be low toxicity with an excellent safety profile,
3- highly effective,
4- nanoviricide therapeutic drugs can be put together in a matter of weeks at low cost in comparison to "big pharma" toxic drugs that take years and millions in development to clinical trials.
Longs are in very good company!
Nanoviricides' approach to MERS: Bind and dismantle
Nanoviricides is smaller than Inovio and Novavax, but it offers a radically different way of combating MERS.
Rather than develop vaccines, Nanoviricides is developing drugs that bind to viruses with virus-binding ligands in an effort to dismantle them. On May 5, Nanoviricides announced that its experimental MERS vaccine, built on that virus-binding technology, was ready for animal testing.
Nanoviricides currently has six main pipeline candidates for influenza, eye viral diseases, HIV, herpes, and dengue -- but none of these candidates have advanced to clinical trials yet. Investors should also note that unlike Inovio and Novavax, Nanoviricides is not backed by any major pharmaceutical or government collaborators.
The Foolish takeaway
Inovio, Novavax, and Nanoviricides are three companies to watch as health officials across the world struggle to understand MERS. If any of these treatments show promise, they could receive accelerated approvals due to the urgent need to treat the disease, especially across the Middle East. Of course, it's important to note that all three of these companies are clinical (or pre-clinical) stage biotechs, so they are not for the faint of heart, and investors may be better served staying on the sidelines and watching these companies.
source: http://www.fool.com/investing/general/2014/05/17/could-these-3-biotechs-help-fight-the-mers-virus.aspx
If a couple of institutions sell...
Yes, nanopatent. The tox studies is the work of people living in West Lafayette, IN, working for BASi, another small company, in a small town, in the heartland of America.
Because nanovicides(R) are low toxicity with an excellent safety profile our rail to market should be FAST. We are looking forward to the Clinical Trials successes (2015) and after that...DengueCide and other nanoviricides approximately every six months.
No, just confidence in the good works performed everyday by our small company, NanoViricides, Inc. (NNVC)!!!